Tufts CSDD Site Experience Survey
The Tufts Center for the Study of Drug Development (Tufts CSDD) is conducting a study on investigative site perspectives and burden associated with Direct-to-Patient (DTP) shipment of study treatments and supplies.
Researchers at Tufts CSDD at the Tufts University School of Medicine, in collaboration with Global Clinical Supplies Group (GCSG), a professional organization of global clinical supplies professionals, are conducting an academic survey to increase understanding of investigative site personnel experiences with the shipment of Investigational Products/Study Treatments to trial participants at their homes—also known as Direct-to-Patient (DtP) shipments of study drug. Your feedback is invaluable in helping to identify pain points and improvement areas.
Please take a few minutes to take survey. In appreciation for your participation, the Tufts CSDD research team will share with you a summary of results when the research concludes. Start the survey: https://tufts.qualtrics.com/jfe/form/SV_2bm7lW1vt6zl53g
Thank you in advance for your participation in this important research effort!
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
CAHtalyst Trial Shows Crenessity Sustains Efficacy in Classic Congenital Adrenal Hyperplasia
July 14th 2025Results from the Phase III CAHtalyst show that patients treated with Crenessity for classic congenital adrenal hyperplasia achieved and maintained lower, more physiologic glucocorticoid doses while keeping key adrenal biomarkers at or below baseline levels.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.
